Groundbreaking Malaria Vaccine Developments: Australian Research Breakthrough and African Manufacturing Strides
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Groundbreaking Malaria Vaccine Developments: Australian Research Breakthrough and African Manufacturing Strides
-
ナレーター：
-
著者：
このコンテンツについて
Researchers at the Walter and Eliza Hall Institute of Medical Research in Australia have identified a promising new target for next-generation malaria vaccines, marking a significant leap in efforts to curb the transmission of this deadly disease. Using advanced cryo-electron microscopy, the team captured for the first time the detailed structure of a protein complex essential for the fertilization of the Plasmodium falciparum parasite inside mosquitoes. This insight enabled the development of an mRNA vaccine candidate that blocks the parasite from reproducing, leading to a reported 99.7 percent reduction in malaria transmission during preclinical studies, according to Anadolu Agency. By targeting the fertilization process, this vaccine candidate offers a new approach that, rather than protecting individuals directly, interrupts the cycle of malaria at its source.
Lead researcher Dr. Melanie Dietrich explained that visualizing the full fertilization complex in its natural form allowed the discovery of a previously unknown critical region, unveiling a powerful new vaccine target. This breakthrough is recognized as a potential game-changer, as malaria continues to kill over 600,000 people annually and affect nearly 300 million worldwide, as recently reported by The Microbiologist and the Walter and Eliza Hall Institute of Medical Research.
The approach is intended not as a replacement but as a complement to existing malaria vaccines, such as the WHO-recommended R21/Matrix-M vaccine, which targets different parasite stages in humans. The transmission-blocking mRNA vaccine would be deployed alongside these, aiming for comprehensive, multilayered protection and significantly reducing malaria's reach. Colin Pouton, co-developer of the vaccine at Monash Institute of Pharmaceutical Sciences, noted that this new avenue illustrates the broader utility of mRNA technology beyond COVID-19 vaccination efforts, Anadolu Agency reports.
Meanwhile, Africa is making strides toward vaccine manufacturing independence. Kigali, Rwanda, is preparing for the launch of BioNTech’s modular mRNA vaccine plant, constructed from prefabricated BioNTainers. According to Finn Partners, this facility will focus on producing vaccines against malaria and tuberculosis, promising not just supply for Rwanda but also exports to neighboring countries. The effort, funded at more than $145 million, forms part of a larger strategy for regional vaccine sovereignty and serves as a milestone in Africa’s ambition to control its health future. This builds on recent partnerships, including Sanofi’s agreement with South Africa’s Biovac in 2024 to locally manufacture polio vaccines.
Elsewhere in Africa, Rwanda is reconsidering its vaccine strategy amid a surprise surge in malaria cases, following years of declining transmission, reports MalariaWorld. The government is now looking closely at vaccine options it had previously declined, seeking to bolster its national malaria response.
In summary, the past two days have seen unprecedented momentum in malaria vaccine research, with Australian scientists paving the way for a new class of transmission-blocking vaccines and African nations advancing efforts to produce vaccines locally. This convergence of scientific innovation and regional self-sufficiency holds promise for making malaria elimination a realistic global goal.
まだレビューはありません